Gilead Sciences, Pharmasset and Roche

Share this article:

Gilead Sciences agreed to pay almost $11 billion for biotech firm Pharmasset, which is developing an all-oral therapy for treating hepatitis C virus. Dubbed PSI-7977, the drug just entered Phase III testing, and analysts say it could become the preferred option for care if it works without the injectable drug interferon, which has flulike side effects.

The FDA said Friday that it was revoking its approval of Roche's Avastin (bevacizumab) for breast cancer after concluding that it has not been shown to be safe and effective for that use. Avastin will remain on the market for certain types of colon, lung, kidney and brain cancer, said FDA commissioner Margaret Hamburg. Doctors can still prescribe it off-label for breast cancer, but insurers may no longer pay for the drug, which costs $88,000 a year. Medicare said it would still provide coverage for that use.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.